Cita APA

Y, S., L, P., N, L., D, C., & L, M. (2020). A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report. Dove Medical Press.

Chicago Style Citation

Y, Sun, Pei L, Luo N, Chen D, i Meng L. A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss As an Acquired Resistance Mechanism to Osimertinib in a Patient With Lung Adenocarcinoma: A Case Report. Dove Medical Press, 2020.

Cita MLA

Y, Sun, et al. A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss As an Acquired Resistance Mechanism to Osimertinib in a Patient With Lung Adenocarcinoma: A Case Report. Dove Medical Press, 2020.